Eli Lilly and Company (NYSE:LLY) is Wafra Inc.’s 9th Largest Position

Wafra Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 50.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 66,041 shares of the company’s stock after selling 66,183 shares during the period. Eli Lilly and Company accounts for about 2.3% of Wafra Inc.’s investment portfolio, making the stock its 9th biggest holding. Wafra Inc.’s holdings in Eli Lilly and Company were worth $38,497,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Manhattan West Asset Management LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $338,000. Allworth Financial LP lifted its holdings in shares of Eli Lilly and Company by 14.6% during the 3rd quarter. Allworth Financial LP now owns 5,288 shares of the company’s stock valued at $2,840,000 after purchasing an additional 672 shares during the last quarter. Key Financial Inc lifted its holdings in shares of Eli Lilly and Company by 5.1% during the 3rd quarter. Key Financial Inc now owns 724 shares of the company’s stock valued at $389,000 after purchasing an additional 35 shares during the last quarter. Wisconsin Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $2,572,000. Finally, Baron Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $213,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY traded down $1.12 during trading on Friday, reaching $770.00. The company’s stock had a trading volume of 1,670,317 shares, compared to its average volume of 2,877,174. The firm has a fifty day simple moving average of $760.66 and a two-hundred day simple moving average of $684.31. The company has a market cap of $731.81 billion, a price-to-earnings ratio of 113.40, a PEG ratio of 1.53 and a beta of 0.37. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1 year low of $419.80 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 13.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be issued a dividend of $1.30 per share. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.68%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analyst Ratings Changes

LLY has been the topic of several research reports. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. Truist Financial upped their target price on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Barclays increased their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $769.53.

Get Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.